News

The open-label Phase II trial will enroll 54 patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL): 27 patients with diffuse large B-cell lymphoma and 27 with follicular lymphoma. Being carried

The company said that patients with advanced refractory solid tumors are being enrolled in the single-agent Phase Ia open-label dose-escalation trial. Currently, being conducted at four sites in

The trial is scheduled to start in the first quarter of 2015. It is designed to evaluate the safety and tolerability of ADXS-HER2 in patients diagnosed with metastatic

The collaboration brings together Amgen’s commitment to and capabilities in advancing new approaches in immuno-oncology and Kite’s industry-leading presence in CAR T cell therapy. Under the terms of

These high-risk patients typically do not respond well to standard therapies. These results were published in The Lancet Oncology. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and

One hundred and sixteen patients in 46 clinical centers from 12 countries participated in the study. Final protocol pre-specified Independent Data Monitoring Committee (IDMC) review on the first

The two parties have also entered into an exclusive license agreement that allows BMS to develop, manufacture and commercialize Calibr’s preclinical compounds resulting from the collaboration. Bristol-Myers Squibb

Benzac treats stubborn acne and prevents new breakouts from forming with salicylic acid, while pharmaceutical-grade East Indian Sandalwood Oil calms and soothes the skin. In a clinical study,

Mr. Shailesh Shah, President and CEO, today states that SOHM received a boost in its restructuring process when the buyer confirmed committed orders for minimum $ 300,000 and